Discovery of potent and liver-selective stearoyl-CoA desaturase (SCD) inhibitors in an acyclic linker series.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2011.10.070PMID 22101133
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.

  2011cited by this paper
• N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.

  2011cited by this paper
• Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.

  2011cited by this paper
• Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase

  2010cited by this paper
• A Multiplexed Cell Assay in HepG2 Cells for the Identification of Delta-5, Delta-6, and Delta-9 Desaturase and Elongase Inhibitors

  2010cited by this paper
• Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.

  2010cited by this paper
• Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats.

  2010cited by this paper
• Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

  2010cited by this paper
• SAR and optimization of thiazole analogs as potent stearoyl-CoA desaturase inhibitors.

  2010cited by this paper
• Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.

  2009cited by this paper
• Thiazole analog as stearoyl-CoA desaturase 1 inhibitor.

  2009cited by this paper
• Stearoyl-CoA desaturase inhibitors: update on patented compounds

  2009cited by this paper
• Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.

  2007cited by this paper
• Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.

  2007cited by this paper
• Role of OATP transporters in the disposition of drugs.

  2007cited by this paper

• tert-BuONO-Promoted Nitrosation of 4-Nitroisoxazole-Based Enamines: Synthesis of 5-Cyanoisoxazoles and Their Application.

  2025cites this paper
• An insight into advances and challenges in the development of potential stearoyl Co-A desaturase 1 inhibitors

  2024cites this paper
• Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects.

  2017cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• An overview of patented small molecule stearoyl coenzyme-A desaturase inhibitors (2009 – 2013)

  2014cites this paper
• Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.

  2014cites this paper
• Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease.

  2014cites this paper
• O-Alkylation of 3-hydroxyisoxazoles predominates under Mitsunobu conditions

  2014cites this paper
• How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusion

  2014cites this paper
• 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.

  2013cites this paper
• Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.

  2013cites this paper
• Role of stearoyl-CoA desaturase-1 in maintaining muscle activity : study of a lesion model for understanding the meatbolic alterations characteristics of amyotrophic lateral sclerosis

  2013cites this paper
• Medicinal chemistry design principles for liver targeting through OATP transporters.

  2013cites this paper
• 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.

  2013cites this paper
• Intestinal targeting of drugs: rational design approaches and challenges.

  2013cites this paper
• Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.

  2012cites this paper